Cerebrolysin — questions, answered plainly.

Cerebrolysin (FPF1070) is a porcine-brain-derived peptide and free amino-acid mixture produced by Ever Neuro Pharma. It is not a single defined molecule — it is a mixture characterised as a 'neurotrophic' preparation.

Cerebrolysin is approved in many countries, particularly across Europe (e.g. Austria, Russia) and Asia, for stroke, traumatic brain injury, and dementia. It is not FDA-approved in the United States.

Ziganshina et al. 2023 (Cochrane Database Syst Rev, PMID 37818733; pooled n=1773 across 7 RCTs) updated the evidence and reported no all-cause mortality benefit in acute ischaemic stroke and a possible increase in non-fatal serious adverse events. This is the most current high-quality synthesis.

Cui 2019 (Cochrane Database Syst Rev, PMID 31710397; pooled n=597 across 6 RCTs) reported modest cognitive improvement signals in vascular dementia but rated the evidence quality as very low. The authors questioned clinical significance.

Approval in many jurisdictions predates the latest Cochrane analyses. Local regulatory bodies and clinical practice in approved-product countries continue to support its use. This profile documents the published evidence base; clinical decisions involving Cerebrolysin are medical decisions for a qualified clinician in the relevant jurisdiction.

Mixture composition rather than a defined molecule. Cochrane reviews report no mortality benefit in stroke and possible increased serious adverse events. Evidence quality across the underlying trials is heterogeneous.